.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
AstraZeneca
Cantor Fitzgerald
Accenture
Moodys
Healthtrust
Queensland Health
Deloitte
Express Scripts
US Department of Justice

Generated: December 16, 2017

DrugPatentWatch Database Preview

TUDORZA PRESSAIR Drug Profile

« Back to Dashboard

When do Tudorza Pressair patents expire, and when can generic versions of Tudorza Pressair launch?

Tudorza Pressair is a drug marketed by Astrazeneca Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has eighty-five patent family members in thirty-eight countries and eleven supplementary protection certificates in ten countries.

The generic ingredient in TUDORZA PRESSAIR is aclidinium bromide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the aclidinium bromide profile page.

Summary for TUDORZA PRESSAIR

Drug patent expirations by year for TUDORZA PRESSAIR

Pharmacology for TUDORZA PRESSAIR

Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes► Subscribe► SubscribeYY► Subscribe
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: TUDORZA PRESSAIR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012► Subscribe► Subscribe
Astrazeneca PharmsTUDORZA PRESSAIRaclidinium bromidePOWDER, METERED;INHALATION202450-001Jul 23, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: TUDORZA PRESSAIR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,897,617Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
6,750,226 Quinuclidine derivatives and their use as muscarinic M3 receptor ligands► Subscribe
8,129,405Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
8,513,279Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
7,750,023Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
7,214,687Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
8,802,699Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
7,358,260Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
9,687,478Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
7,196,098Quinuclidine derivatives and medicinal compositions containing the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TUDORZA PRESSAIR

Country Document Number Estimated Expiration
Bulgaria65565► Subscribe
Portugal1616592► Subscribe
Brazil0012434► Subscribe
Bulgaria106301► Subscribe
Australia779881► Subscribe
Hong Kong1042487► Subscribe
BrazilPI0012434► Subscribe
Australia6433000► Subscribe
Russian Federation2306312► Subscribe
Cyprus1110984► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TUDORZA PRESSAIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90002-2Sweden► SubscribePRODUCT NAME: AKLIDINIUMSALT MED FARMACEUTISKT ACCEPTABEL ANJON AV EN- ELLER FLERVAERD SYRA, SPECIELLT AKLIDINIUMBROMID; REG. NO/DATE: EU/1/12/778/001 20120720
1Finland► Subscribe
2013001,C1200431Lithuania► SubscribePRODUCT NAME: ACLIDINII BROMIDUM; REGISTRATION NO/DATE: EU/1/12/778/001 - EU/1/12/778/003, 2012 07 20 EU/1/12/781/001 - EU/1/12/781/003 20120720
C0001France► SubscribePRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT, EN PARTICULIER LE BROMURE D'ACLIDINIUM; REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720
1200431/01Switzerland► SubscribePRODUCT NAME: ACLIDINIUM; REGISTRATION NO/DATE: SWISSMEDIC 62590 25.04.2013
13/002Ireland► SubscribePRODUCT NAME: ACLIDINIUM SALT WITH A PHARMACEUTICALLY ACCEPTABLE ANION OF A MONO OR POLYVALENT ACID ESPECIALLY AS ACLIDINIUM BROMIDE; NAT REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720; FIRST REGISTRATION NO/DATE: EU/1/12/781/001-003 20/07/2012 EUROPEAN UNION EU/1/12/778/001-003 20/07/2012 EUROPEAN UNION EU/1/12/781/001-003 20120720
2013 00002Denmark► Subscribe
2013Austria► SubscribePRODUCT NAME: ACLIDINIUMSALZ MIT EINEM PHARMAZEUTISCH ANNEHMBAREN ANION EINER MONO- ODER POLYVALENTEN SAEURE INSBESONDERE ALS ACLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/12/778/001-003 EU/1/12/781/001-003 20120720
2013001Lithuania► SubscribePRODUCT NAME: ACLIDINII BROMIDUM; REGISTRATION NO/DATE: EU/1/12/778/001 - EU/1/12/778/003, 2012 07 20 EU/1/12/781/001 - EU/1/12/781/003 20120720
00573Netherlands► SubscribePRODUCT NAME: ACLIDINIUMZOUT MET EEN FARMACEUTISCH AANVAARDBAAR ANION VAN EEN EEN- OF MEERWAARDIG ZUUR, IN HET BIJZONDER ACLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/12/778/001-003EU/1/12/781/001-003 2012200720
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
US Army
Dow
Medtronic
Express Scripts
Cerilliant
US Department of Justice
Merck
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot